Ocuphire Pharma Inc. Stock
Your prediction
Ocuphire Pharma Inc. Stock
There is an upward development for Ocuphire Pharma Inc. compared to yesterday, with an increase of €0.080 (1.700%).
Our community identified positive and negative aspects for Ocuphire Pharma Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Ocuphire Pharma Inc. stock. On the other hand our users think that "Innovation" could be a problem in the future.
Pros and Cons of Ocuphire Pharma Inc. in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ocuphire Pharma Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ocuphire Pharma Inc. | 1.700% | 16.244% | 5.896% | 620.126% | 172.295% | -7.475% | - |
| Immunic Inc. | 6.000% | 0.806% | -21.011% | 26.263% | 132.558% | -23.954% | -92.026% |
| NanoViricides Inc. | -1.210% | 3.774% | -17.085% | -11.765% | -11.290% | -24.312% | -78.482% |
| Actinium Pharmaceuticals Inc. | -2.800% | 8.441% | -8.506% | -17.705% | -23.364% | -88.922% | -86.496% |
Comments
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at HC Wainwright from $20.00 to $18.00. They now have a "buy" rating on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Alliance Global Partners from $24.00 to $20.00. They now have a "buy" rating on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
